查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1935257

中枢神经系统特异性反义寡核苷酸市场（依药物、适应症、通路和地区划分）

CNS Specific Antisense Oligonucleotide Market, By Drug, By Indication, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格
简介目录

中枢神经系统特异性反义寡核苷酸市场预计在 2026 年达到 32 亿美元，预计到 2033 年将达到 61 亿美元，2026 年至 2033 年的复合年增长率为 9.8%。

报告覆盖范围 报告详情
基准年： 2025 2026年市场规模： 32亿美元
历史数据时期： 2020年至2024年 预测期： 2026年至2033年
预测期（2026-2033年）复合年增长率： 9.80% 2033 年的预测值： 61亿美元

反义寡核苷酸是能够抑制传讯RNA（mRNA）表现的合成核酸链。它们透过抑制前驱mRNA的剪接，发挥蛋白质修復和修饰等功能。反义寡核苷酸是一种旨在预防神经退化性疾病发生和延缓其进展的新型治疗方法。

市场动态

神经退化性疾病的日益普遍是推动中枢神经系统（CNS）特异性反义寡核苷酸市场成长的主要因素。根据老年痴呆症协会的情况说明书，2018年估计有570万美国人被诊断出患有老年痴呆症失智症。此外，用于治疗中枢神经系统疾病及相关罕见疾病的丰富产品平臺也预计将推动市场成长。例如，2018年12月，百健（Biogen）和Ionis Pharmaceuticals联合研发的IONIS-SOD1Rx（BIIB067）完成了I期临床试验，预计于2020年上市。

本次调查的主要特点

  • 本报告对中枢神经系统特异性反义寡核苷酸市场进行了详细分析，以 2017 年为基准年，给出了预测期（2018-2026 年）内的市场规模和復合年增长率（%）。
  • 该报告还重点介绍了各个细分市场的潜在商机，并概述了该市场具有吸引力的投资提案矩阵。
  • 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要参与者采取的竞争策略的重要见解。
  • 本报告根据以下参数对全球中枢神经系统特异性反义寡核苷酸市场的主要企业进行了分析：公司概况、财务绩效、产品系列、市场地位、分销策略、关键发展、策略和未来计划。
  • 本报告的研究结果将帮助负责人和经营团队就即将推出的产品、技术升级、市场扩张和行销策略做出明智的决策。
  • 这份全球中枢神经系统特异性反义寡核苷酸市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
  • 相关人员可以透过各种策略矩阵轻鬆做出决策，这些矩阵用于分析中枢神经系统特异性反义寡核苷酸市场。

目录

第一章 研究目标与前提条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场概览

  • 报告概述
    • 市场定义和范围
  • 执行摘要

第三章 市场动态、监理及趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 法规环境
  • 产品上市及核准情况
  • PEST分析
  • 波特分析
  • 市场机会
  • 法规环境
  • 重大进展
  • 产业趋势

4. 2020-2033年全球中枢神经系统特异性反义寡核苷酸市场（依药物类型划分）

  • 已通过核准的
  • 开发中

5. 2020-2033年全球中枢神经系统特异性反义寡核苷酸市场（依适应症划分）

  • 遗传性转甲状腺素蛋白类淀粉沉积症（hATTR）/神经病变
  • 脊髓性肌肉萎缩症
  • 亨丁顿舞蹈症

6. 2020-2033年全球中枢神经系统特异性反义寡核苷酸市场（依通路划分）

  • 医院药房
  • 零售药房
  • 网路药房

7. 2020-2033年全球中枢神经系统特异性反义寡核苷酸市场（依地区划分）

  • 北美洲
    • 我们
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第八章 竞争情势

  • Alnylam Pharmaceuticals Inc.
  • Sarepta Therapeutics Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Stroke Therapeutic Inc.
  • Dynacure
  • ProQR Therapeutics NV
  • Q-STATE BIOSCIENCES, INC.

第九章 分析师建议

  • 机会
  • 分析师观点
  • Coherent Opportunity Map

第十章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于本公司
简介目录
Product Code: CMI2477

CNS Specific Antisense Oligonucleotide Market is estimated to be valued at USD 3,200 Mn in 2026 and is expected to reach USD 6,100 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 3,200 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 9.80% 2033 Value Projection: USD 6,100 Mn

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.

Market Dynamics

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

Key features of the study

  • This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (USD million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market

Market Segmentation

  • Drug Insights (Revenue, USD Mn, 2026 - 2033)
    • Approved
    • Pipeline
  • Indication Insights (Revenue, USD Mn, 2026 - 2033)
    • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Spinal Muscular Atrophy
    • Huntington's Disease
  • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Regional Insights (Revenue, USD Mn, 2026 - 2033)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • North Africa
    • Central Africa
    • South Africa
  • Key Players Insights
    • Alnylam Pharmaceuticals Inc.
    • Sarepta Therapeutics Inc.
    • Biogen Inc.
    • Ionis Pharmaceuticals Inc.
    • Wave Life Sciences Ltd.
    • Stroke Therapeutic Inc.
    • Dynacure
    • ProQR Therapeutics N.V.
    • Q-STATE BIOSCIENCES, INC.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global CNS Specific Antisense Oligonucleotide Market, By Drug
    • Global CNS Specific Antisense Oligonucleotide Market, By Indication
    • Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel
    • Global CNS Specific Antisense Oligonucleotide Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trend

4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Approved
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Pipeline
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Spinal Muscular Atrophy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Huntington's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel Type, 2020-2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2020 - 2033, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

8. Competitive Landscape

  • Alnylam Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sarepta Therapeutics Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ionis Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Wave Life Sciences Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Stroke Therapeutic Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dynacure
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ProQR Therapeutics N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Q-STATE BIOSCIENCES, INC.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us